Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes Mellitus
The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin glargine on lowering the blood sugar level.
- Trial name
- NCT00447213
- Testing
- Insulin glargine, Human Insulin Inhalation Powder, Injectable Insulin
- Where
- 5 sites in Japan, Taiwan
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients Secondary Objective: To evaluate the insulin glulisine doses To assess the patient satisfaction
- Trial name
- PORTAL 1 (NCT00964574)
- Testing
- INSULIN GLULISINE (HMR1964), INSULIN GLARGINE
- Where
- Belarus
- Volunteers
- 68 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.
- Trial name
- PREDICTIVE™ (NCT00704574)
- Testing
- insulin detemir
- Where
- Sweden
- Volunteers
- 159 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study
Continuous Subcutaneous Insulin Infusion (CSII) via insulin pump therapy has been shown to improve quality of life and glucose control in many patients with diabetes opting for this treatment modality.
- Trial name
- NCT02662842
- Testing
- FlowSmart Infusion Set, Current Infusion Set
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492153
- Testing
- biphasic human insulin, isophane human insulin, human soluble insulin
- Where
- Indonesia
- Volunteers
- 1,981 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Control-IQ Observational (CLIO) Post-Approval Study
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
- Trial name
- CLIO (NCT04503174)
- Testing
- t:slim X2 pump with Control-IQ technology
- Where
- United States
- Volunteers
- 3,157 people
- Sponsor
- Tandem Diabetes Care, Inc.
Healthy
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
The purpose of this study is to assess the bioequivalence (similarity of the drug amount in blood among the formulations) of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin…
- Trial name
- NCT02077803
- Testing
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type 1 or Type 2 Diabetes
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
From Jan 2022 to June 2022, 120 subjects (22-75 years of age, mean ±standard deviation [SD] of 53.20 ±14.49 years) with type 1 or type 2 diabetes participated in the study in P.R. China.
- Trial name
- NCT05995756
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Healthy, Prediabetic State (IGT)
Noninvasive Transcutaneous Glucometer Development
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
- Conditions
- Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT01168076
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Easy Diabetes Treatment Study 1
A 26-week, multicenter, parallel two-arm, randomized controlled trial of the glycemic outcomes of individualized treatment support in patients with type 2 diabetes.
- Trial name
- EASY-1 (NCT03258268)
- Testing
- Standard of Care with EASY DSS, Standard of Care without EASY DSS
- Where
- 3 sites in Sweden
- Volunteers
- 311 people
- Sponsor
- Läkarexpressen AB
Atherosclerosis, Diabetes Mellitus
TART - Troglitazone Atherosclerosis Regression Trial
The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
- Trial name
- NCT00116545
- Testing
- troglitazone
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Parke-Davis
Diabetes Mellitus, Type 2
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects
1. Study Objective: The objective of this study is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics, and food effect of HGR4113 after single and multiple oral administration in healthy…
- Trial name
- NCT05642377
- Testing
- HGR4113
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaceum
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.
- Trial name
- DAWN (NCT03794973)
- Testing
- TOL-3021
- Where
- United States
- Sponsor
- Tolerion, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Type 1 Diabetes, Hypoglycemia
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
The purpose of this study is to determine whether ZT-01 increases the glucagon response to hypoglycemia in type 1 diabetes (T1D).
- Trial name
- NCT05007977
- Testing
- ZT-01 low dose, ZT-01 high dose
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Zucara Therapeutics Inc.
Non-Insulin-Dependent Diabetes Mellitus
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients.
- Trial name
- NCT00318656
- Testing
- rosiglitazone-metformin fixed dose combination, metformin + glimepiride
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
- Trial name
- T1GER (NCT02846545)
- Testing
- Golimumab
- Where
- 33 sites in United States
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes
Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System
The Quo-Test A1C Analyzer and Reagent Test System (Quo-Test A1C System) are intended for the in-vitro quantitative determination of glycated hemoglobin in whole blood samples obtained from fingerstick or venous samples for…
- Trial name
- NCT01829061
- Where
- 3 sites in United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Quotient Diagnostics Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.